Update on Dupilumab: HSE Management Supports Reimbursement

Less than a month from the last major development, Dupilumab receives green light for funding In a statement to the ISF and healthcare professionals this afternoon, the HSE notified patients that the Executive Management Team has supported reimbursement of Dupilumab under High Tech (Drugs Scheme)¬†Arrangements. Availability of the new ‘first-in-class’ treatment will be “subject to […]